CW July 2005
Volume 14Issue Number 7 July 2005 ISSN 10593802 Toxicity Not A Major Hurdle for Weekly Docetaxel Immediately Post-ProstatectomyInterim data from an ongoing open-label phase II study of docetaxel, 35 mg/m2 in men at high-risk for recurrence indicates that the treatment is reasonably well-tolerated, and that side effects are largely moderate and reversible, according to a report at the American Urological Association 2005 Annual Meeting.
Go to Previous Page Go to Next Page Source & Additional Reading A. Kibel, American Urological Association 2005 Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
